Bevacizumab

Vladimir Beljanski

doi:10.1016/B978-008055232-3.63725-0

Bevacizumab

Vladimir Beljanski

Research output: Chapter in Book/Report/Conference proceeding › Chapter

2 Scopus citations

Abstract

Bevacizumab is a monoclonal antibody with antiangiogenesis properties that is employed for the treatment of solid tumors. By attaching to vascular endothelial growth factor (VEGF), bevacizumab prevents it from stimulating the growth of blood vessels that are required for tumor growth. Bevacizumab is approved for the treatment of. © 2007

Original language	English
Title of host publication	xPharm
Subtitle of host publication	The Comprehensive Pharmacology Reference
Editors	S.J. Enna, David B. Bylund
Publisher	Elsevier Inc.
Pages	1-6
Number of pages	6
ISBN (Print)	9780080552323
DOIs	https://doi.org/10.1016/B978-008055232-3.63725-0
State	Published - 2007
Externally published	Yes

ASJC Scopus Subject Areas

General Pharmacology, Toxicology and Pharmaceutics

Disciplines

Medicine and Health Sciences

Access to Document

10.1016/B978-008055232-3.63725-0

Cite this

@inbook{7b882440e6b54c9c85fc5308b52a1ec8,

title = "Bevacizumab",

abstract = "Bevacizumab is a monoclonal antibody with antiangiogenesis properties that is employed for the treatment of solid tumors. By attaching to vascular endothelial growth factor (VEGF), bevacizumab prevents it from stimulating the growth of blood vessels that are required for tumor growth. Bevacizumab is approved for the treatment of. {\textcopyright} 2007",

author = "Vladimir Beljanski",

year = "2007",

doi = "10.1016/B978-008055232-3.63725-0",

language = "English",

isbn = "9780080552323",

pages = "1--6",

editor = "S.J. Enna and Bylund, \{David B.\}",

booktitle = "xPharm",

publisher = "Elsevier Inc.",

address = "United States",

}

TY - CHAP

T1 - Bevacizumab

AU - Beljanski, Vladimir

PY - 2007

Y1 - 2007

N2 - Bevacizumab is a monoclonal antibody with antiangiogenesis properties that is employed for the treatment of solid tumors. By attaching to vascular endothelial growth factor (VEGF), bevacizumab prevents it from stimulating the growth of blood vessels that are required for tumor growth. Bevacizumab is approved for the treatment of. © 2007

AB - Bevacizumab is a monoclonal antibody with antiangiogenesis properties that is employed for the treatment of solid tumors. By attaching to vascular endothelial growth factor (VEGF), bevacizumab prevents it from stimulating the growth of blood vessels that are required for tumor growth. Bevacizumab is approved for the treatment of. © 2007

UR - https://www.scopus.com/pages/publications/84884120658

UR - https://www.scopus.com/pages/publications/84884120658#tab=citedBy

U2 - 10.1016/B978-008055232-3.63725-0

DO - 10.1016/B978-008055232-3.63725-0

M3 - Chapter

AN - SCOPUS:84884120658

SN - 9780080552323

SP - 1

EP - 6

BT - xPharm

A2 - Enna, S.J.

A2 - Bylund, David B.

PB - Elsevier Inc.

ER -

Bevacizumab

Abstract

ASJC Scopus Subject Areas

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this